NasdaqCM - Nasdaq Real Time Price USD

Vivani Medical, Inc. (VANI)

Compare
1.2201 -0.0099 (-0.80%)
As of 12:23 PM EDT. Market Open.
Loading Chart for VANI
DELL
  • Previous Close 1.2300
  • Open 1.2300
  • Bid 0.8856 x 200
  • Ask 1.5700 x 200
  • Day's Range 1.2200 - 1.2399
  • 52 Week Range 0.8400 - 7.8000
  • Volume 15,768
  • Avg. Volume 88,800
  • Market Cap (intraday) 67.418M
  • Beta (5Y Monthly) 3.61
  • PE Ratio (TTM) --
  • EPS (TTM) -0.4600
  • Earnings Date Nov 12, 2024 - Nov 18, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.

www.vivani.com

36

Full Time Employees

December 31

Fiscal Year Ends

Recent News: VANI

View More

Performance Overview: VANI

Trailing total returns as of 9/23/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

VANI
19.62%
S&P 500
19.79%

1-Year Return

VANI
28.43%
S&P 500
32.26%

3-Year Return

VANI
87.97%
S&P 500
29.98%

5-Year Return

VANI
94.29%
S&P 500
90.96%

Compare To: VANI

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: VANI

View More

Valuation Measures

Annual
As of 9/20/2024
  • Market Cap

    67.96M

  • Enterprise Value

    63.08M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    2.85

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    -3.93

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -29.29%

  • Return on Equity (ttm)

    -86.10%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -24.2M

  • Diluted EPS (ttm)

    -0.4600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    24.92M

  • Total Debt/Equity (mrq)

    84.10%

  • Levered Free Cash Flow (ttm)

    -14.29M

Research Analysis: VANI

View More

Earnings Per Share

Consensus EPS
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Company Insights: VANI

Research Reports: VANI

View More
  • Daily – Vickers Top Insider Picks for 03/18/2024

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     
  • Daily – Vickers Top Insider Picks for 03/15/2024

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     
  • Daily – Vickers Top Insider Picks for 03/14/2024

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     
  • Daily – Vickers Top Insider Picks for 03/13/2024

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     

People Also Watch